MedPath

A phase II study of weekly paclitaxel for advanced or recurrent esophageal cancer

Phase 2
Conditions
advanced or reccurent esophageal cancer
Registration Number
JPRN-UMIN000009807
Lead Sponsor
Medical Oncology, Hirosaki University Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

severe bone marrow suppression active infection uncontrolled comorbidities acute inflammatory disease interstitial pneumonia or pulmonary fibrosis symptomatic metastases of the central nervous system with a history of allergic reaction to polyoxyethylene-castor oil under administration of disulfiram, cyanamide and procarbazine hydrochloride pregnant or nursing woman any patients judged by the investigator to be unfit to participate in the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
response rate
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath